|
Join us in Nashville, TN, USA! The AUGS/IUGA Scientific Meeting combines the best of AUGS' and IUGA's annual scientific meetings into this year's joint meeting. The Joint Program Committee is planning a meeting that brings together international, multi-disciplinary speakers to discuss and reflect on the current "hot topics" in the field. A robust and interactive program including hands-on workshops, abstract presentations, panel discussions, keynote lectures and networking events awaits you in Nashville, TN, USA. |
|
|
|
|
Preliminary Program now available online. |
|
|
|
The May issue of the International Urogynecology Journal is now available! Don't miss out on the latest news and research in the international field of urogynecology!
Click here to find out more about the journal.
If you are a member of IUGA, click here to access the journal.
If you are not a member of IUGA, click here to join!
Mark your calendar to join us June 12 at 7:00pm UTC for the live broadcast of the IUGA Webinar: Making the Transition From Trainee to Early Career Professional. Hosted by Debjyoti Karmakar with special guests Wenche Klerkx from the Netherlands and Gans Thiagamoorthy from the UK, the webinar will focus on helping trainees make the transition to independent consultants by focusing on strategies to cope with the fear of working independently and unique challenges that a consultant faces (as compared to being a trainee).
Dial in instructions will be available one week prior to the webinar. Can't join us for the live broadcast? No worries, the recording of the webinar will be available on the IUGA Academy!
We invite you to submit questions to be addressed during the webinar to
We are now requesting intents-to-bid for the IUGA Annual Meeting in 2023 which will take place in Europe. The intent-to-bid must be submitted in electronic form before/on May 25, 2019 to David Casalod, Executive Director at
For more information, click here.
The third version of the National Institute for Health and Clinical Excellence (NICE) guideline on the management of urinary incontinence and pelvic organ prolapse in women was released on 2 April 2019.
It includes pelvic organ prolapse for the first time, as the earlier two versions (2006 and 2013) only covered urinary incontinence. It advocates conservative measures before offering surgery and outlines local as well as regional multidisciplinary team meetings (MDT) for simple and complex cases. The guideline specifies national database documentation of surgery, including safety and effectiveness, and notification of mesh complications and also outlines the need for specialized centers for the assessment and management of mesh related complications.
The guideline includes retropubic bottom up mid-urethral tape as an option for surgical management for stress incontinence of urine after colposuspension, autologous sling, and urethral bulking agents. The guideline included vaginal mesh for recurrent anterior compartment prolapse in women with adequate vault support in whom an abdominal approach is contra-indicated after proper counseling and discussion at a regional multidisciplinary team meeting (MDT). The guideline does not advocate prophylactic continence procedures at the time of prolapse surgery. While the guideline does not discourage performing continence procedures alongside surgery for anterior and apical compartment prolapse for patients with concomitant urodynamic stress incontinence of urine, it recommends adequate patient counseling about the uncertain benefit and potential for complications.
DEADLINE EXTENDED: April 15, 2019
We understand how busy life can get, so we are giving you the weekend to finalize your submission! Don't miss out on your chance to present your work to an international audience of approximately 2,000 healthcare professionals working in the field of urogynecology!
Abstracts can be submitted for oral presentations, oral posters, video presentations, scientific salons and posters.
Categories include:
• Anatomy
• Anorectal Disorders
• Basic Science
• Conservative Management
• Education
• Epidemiology/Quality of Life
• Evaluation & Training
• Healthcare Delivery/Systems
• Public Health/Population Studies (not covered in Epidemiology)
• Sexual Function/Sexual Pain
• Surgical
For more information or to submit your abstract, click here
Don't miss out on the latest news and research in the international field of urogynecology! Click here to read the newest issue of IUJ!
Observational learning is a great way to enhance your skill set, but the opportunity to observe the best in the field can be expensive! That’s why we offer 3 IUGA Observership Grants to offset the costs of visiting a site with proven expertise in your expressed area of interest in urogynecology.
Observership grants help defray travel and living expenses during a 2-4 week observership at an IUGA-approved host site. Preparing your application and making arrangements with an approved host site (or getting a site approved) can take some time. Individuals interested in applying are therefore encouraged to start the application process early.
One observership will be awarded in each of the following categories:
- $4,000 USD for a trainee, fellow, or physician-in-training
- $4000 USD for a consultant from a Least Developed Country (low and lower-middle income countries as defined by the World Bank)
- $2,000 for any IUGA member
Applications must be received by 11:59pm CDT on Friday, September 6, 2019.
Genitourinary syndrome of menopause (GSM) is more prevalent in breast cancer survivors yet is often undiagnosed and untreated. The lack of safety evidence for vaginal hormone therapies in women with or at high risk for breast cancer often results in the lack of treatment, which can adversely affect quality of life and intimate relationships. A consensus panel of 16 experts from the North American Menopause Society and the International Society for the Study of Women’s Sexual Health therefore undertook an iterative process which included literature reviews, presentations, debate, and discussion of divergent opinions to develop consensus recommendations for clinicians. The recommendations were published in June (2018) in Menopause: The Journal of The North American Menopause Society.
The panel concluded that nonhormonal treatments are generally first-line therapies for treating GSM in women with or at high risk for breast cancer. The article provides recommendations for specific patient populations including women with a high risk for breast cancer, women with ER-positive breast cancers, women with triple-negative breast cancers, and women with metastatic disease.
Faubion S, Larkin L, Stuenkel C, Bachmann G et al. Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer. Consensus recommendations from The North American Menopause Society and The International Society for the Study of Women’s Sexual Health. Menopause. 2018;25(6):596-608.